BAXTER INTERNATIONAL INC (BAX) Stock Fundamental Analysis

NYSE:BAX • US0718131099

21.58 USD
+0.24 (+1.12%)
At close: Feb 20, 2026
21.83 USD
+0.25 (+1.16%)
After Hours: 2/20/2026, 8:18:10 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, BAX scores 3 out of 10 in our fundamental rating. BAX was compared to 185 industry peers in the Health Care Equipment & Supplies industry. BAX has a bad profitability rating. Also its financial health evaluation is rather negative. BAX is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year BAX was profitable.
  • In the past year BAX had a positive cash flow from operations.
  • In multiple years BAX reported negative net income over the last 5 years.
  • BAX had a positive operating cash flow in 4 of the past 5 years.
BAX Yearly Net Income VS EBIT VS OCF VS FCFBAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B -2B 4B

1.2 Ratios

  • The Return On Assets of BAX (-1.62%) is better than 70.27% of its industry peers.
  • BAX has a Return On Equity of -4.71%. This is in the better half of the industry: BAX outperforms 70.81% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 3.05%, BAX is in the better half of the industry, outperforming 70.27% of the companies in the same industry.
  • BAX had an Average Return On Invested Capital over the past 3 years of 3.50%. This is significantly below the industry average of 8.75%.
Industry RankSector Rank
ROA -1.62%
ROE -4.71%
ROIC 3.05%
ROA(3y)-0.58%
ROA(5y)1.52%
ROE(3y)-6.47%
ROE(5y)1.48%
ROIC(3y)3.5%
ROIC(5y)4.71%
BAX Yearly ROA, ROE, ROICBAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40

1.3 Margins

  • BAX's Operating Margin of 6.40% is fine compared to the rest of the industry. BAX outperforms 70.81% of its industry peers.
  • In the last couple of years the Operating Margin of BAX has declined.
  • BAX has a worse Gross Margin (35.05%) than 72.97% of its industry peers.
  • BAX's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 6.4%
PM (TTM) N/A
GM 35.05%
OM growth 3Y-19.11%
OM growth 5Y-13.17%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.94%
GM growth 5Y-2.16%
BAX Yearly Profit, Operating, Gross MarginsBAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BAX is destroying value.
  • There is no outstanding debt for BAX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BAX Yearly Shares OutstandingBAX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M
BAX Yearly Total Debt VS Total AssetsBAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

2.2 Solvency

  • BAX has an Altman-Z score of 2.28. This is not the best score and indicates that BAX is in the grey zone with still only limited risk for bankruptcy at the moment.
  • BAX's Altman-Z score of 2.28 is fine compared to the rest of the industry. BAX outperforms 66.49% of its industry peers.
  • The Debt to FCF ratio of BAX is 38.94, which is on the high side as it means it would take BAX, 38.94 years of fcf income to pay off all of its debts.
  • BAX has a Debt to FCF ratio of 38.94. This is in the better half of the industry: BAX outperforms 67.57% of its industry peers.
  • BAX has a Debt/Equity ratio of 1.21. This is a high value indicating a heavy dependency on external financing.
  • BAX has a worse Debt to Equity ratio (1.21) than 77.30% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.21
Debt/FCF 38.94
Altman-Z 2.28
ROIC/WACC0.4
WACC7.64%
BAX Yearly LT Debt VS Equity VS FCFBAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.3 Liquidity

  • BAX has a Current Ratio of 1.84. This is a normal value and indicates that BAX is financially healthy and should not expect problems in meeting its short term obligations.
  • BAX's Current ratio of 1.84 is on the low side compared to the rest of the industry. BAX is outperformed by 65.95% of its industry peers.
  • BAX has a Quick Ratio of 1.18. This is a normal value and indicates that BAX is financially healthy and should not expect problems in meeting its short term obligations.
  • BAX has a Quick ratio of 1.18. This is in the lower half of the industry: BAX underperforms 68.11% of its industry peers.
Industry RankSector Rank
Current Ratio 1.84
Quick Ratio 1.18
BAX Yearly Current Assets VS Current LiabilitesBAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • BAX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.24%.
  • The Earnings Per Share has been decreasing by -5.98% on average over the past years.
EPS 1Y (TTM)-16.24%
EPS 3Y-13.44%
EPS 5Y-5.98%
EPS Q2Q%-24.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%8.03%

3.2 Future

  • BAX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.95% yearly.
  • Based on estimates for the next years, BAX will show a small growth in Revenue. The Revenue will grow by 2.22% on average per year.
EPS Next Y-0.01%
EPS Next 2Y3.92%
EPS Next 3Y5.38%
EPS Next 5Y6.95%
Revenue Next Year2.3%
Revenue Next 2Y2.29%
Revenue Next 3Y2.36%
Revenue Next 5Y2.22%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
BAX Yearly Revenue VS EstimatesBAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 5B 10B 15B
BAX Yearly EPS VS EstimatesBAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 9.51, which indicates a very decent valuation of BAX.
  • Compared to the rest of the industry, the Price/Earnings ratio of BAX indicates a rather cheap valuation: BAX is cheaper than 95.68% of the companies listed in the same industry.
  • BAX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.99.
  • With a Price/Forward Earnings ratio of 9.51, the valuation of BAX can be described as very reasonable.
  • Based on the Price/Forward Earnings ratio, BAX is valued cheaply inside the industry as 95.68% of the companies are valued more expensively.
  • BAX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.06.
Industry RankSector Rank
PE 9.51
Fwd PE 9.51
BAX Price Earnings VS Forward Price EarningsBAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • 88.65% of the companies in the same industry are more expensive than BAX, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, BAX is valued a bit cheaper than 75.14% of the companies in the same industry.
Industry RankSector Rank
P/FCF 45.46
EV/EBITDA 11.08
BAX Per share dataBAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.92%
EPS Next 3Y5.38%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. Dividend

5.1 Amount

  • With a yearly dividend of 0.18%, BAX is not a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 0.20, BAX pays a better dividend. On top of this BAX pays more dividend than 90.27% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.85, BAX's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.18%

5.2 History

  • The dividend of BAX is nicely growing with an annual growth rate of 6.89%!
  • BAX has paid a dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)6.89%
Div Incr Years0
Div Non Decr Years0
BAX Yearly Dividends per shareBAX Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • BAX has negative earnings and hence a negative payout ratio. The dividend may be in danger.
  • BAX's earnings are growing around the same pace than its dividend. As long as the earnings growth is kept the dividend growth is sustainable.
DP-119.65%
EPS Next 2Y3.92%
EPS Next 3Y5.38%
BAX Yearly Income VS Free CF VS DividendBAX Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B -2B 4B

More info and screens

Find the best dividend stocksShow peers with best dividend

BAXTER INTERNATIONAL INC

NYSE:BAX (2/20/2026, 8:18:10 PM)

After market: 21.83 +0.25 (+1.16%)

21.58

+0.24 (+1.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-12
Earnings (Next)04-29
Inst Owners102.74%
Inst Owner Change5.62%
Ins Owners0.28%
Ins Owner Change10.87%
Market Cap11.09B
Revenue(TTM)N/A
Net Income(TTM)-341.00M
Analysts55.2
Price Target23.61 (9.41%)
Short Float %6.95%
Short Ratio3.89
Dividend
Industry RankSector Rank
Dividend Yield 0.18%
Yearly Dividend1.16
Dividend Growth(5Y)6.89%
DP-119.65%
Div Incr Years0
Div Non Decr Years0
Ex-Date02-27
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.96%
Min EPS beat(2)-4.25%
Max EPS beat(2)14.16%
EPS beat(4)3
Avg EPS beat(4)8.34%
Min EPS beat(4)-4.25%
Max EPS beat(4)14.16%
EPS beat(8)7
Avg EPS beat(8)5.47%
EPS beat(12)9
Avg EPS beat(12)3.78%
EPS beat(16)11
Avg EPS beat(16)3.66%
Revenue beat(2)0
Avg Revenue beat(2)-1.91%
Min Revenue beat(2)-2.38%
Max Revenue beat(2)-1.44%
Revenue beat(4)2
Avg Revenue beat(4)-0.36%
Min Revenue beat(4)-2.38%
Max Revenue beat(4)1.93%
Revenue beat(8)5
Avg Revenue beat(8)-0.06%
Revenue beat(12)6
Avg Revenue beat(12)-0.48%
Revenue beat(16)6
Avg Revenue beat(16)-2.41%
PT rev (1m)-3.84%
PT rev (3m)-18.18%
EPS NQ rev (1m)-0.13%
EPS NQ rev (3m)0.52%
EPS NY rev (1m)0.04%
EPS NY rev (3m)-0.68%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.47%
Valuation
Industry RankSector Rank
PE 9.51
Fwd PE 9.51
P/S 1.01
P/FCF 45.46
P/OCF 14.81
P/B 1.53
P/tB N/A
EV/EBITDA 11.08
EPS(TTM)2.27
EY10.52%
EPS(NY)2.27
Fwd EY10.52%
FCF(TTM)0.47
FCFY2.2%
OCF(TTM)1.46
OCFY6.75%
SpS21.44
BVpS14.09
TBVpS-5.77
PEG (NY)N/A
PEG (5Y)N/A
Graham Number26.82
Profitability
Industry RankSector Rank
ROA -1.62%
ROE -4.71%
ROCE 4.08%
ROIC 3.05%
ROICexc 3.39%
ROICexgc 9.84%
OM 6.4%
PM (TTM) N/A
GM 35.05%
FCFM 2.21%
ROA(3y)-0.58%
ROA(5y)1.52%
ROE(3y)-6.47%
ROE(5y)1.48%
ROIC(3y)3.5%
ROIC(5y)4.71%
ROICexc(3y)3.9%
ROICexc(5y)5.53%
ROICexgc(3y)10.35%
ROICexgc(5y)12.85%
ROCE(3y)4.85%
ROCE(5y)6.42%
ROICexgc growth 3Y-24.28%
ROICexgc growth 5Y-17.95%
ROICexc growth 3Y-15.78%
ROICexc growth 5Y-22.54%
OM growth 3Y-19.11%
OM growth 5Y-13.17%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.94%
GM growth 5Y-2.16%
F-Score3
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity 1.21
Debt/FCF 38.94
Debt/EBITDA 5.17
Cap/Depr 51.22%
Cap/Sales 4.58%
Interest Coverage 250
Cash Conversion 44.27%
Profit Quality N/A
Current Ratio 1.84
Quick Ratio 1.18
Altman-Z 2.28
F-Score3
WACC7.64%
ROIC/WACC0.4
Cap/Depr(3y)49.31%
Cap/Depr(5y)63.51%
Cap/Sales(3y)5.12%
Cap/Sales(5y)5.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.24%
EPS 3Y-13.44%
EPS 5Y-5.98%
EPS Q2Q%-24.14%
EPS Next Y-0.01%
EPS Next 2Y3.92%
EPS Next 3Y5.38%
EPS Next 5Y6.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%8.03%
Revenue Next Year2.3%
Revenue Next 2Y2.29%
Revenue Next 3Y2.36%
Revenue Next 5Y2.22%
EBIT growth 1Y-43.57%
EBIT growth 3Y-23.92%
EBIT growth 5Y-14.31%
EBIT Next Year53.79%
EBIT Next 3Y17.7%
EBIT Next 5Y17.33%
FCF growth 1Y-73.82%
FCF growth 3Y-27.1%
FCF growth 5Y-16.46%
OCF growth 1Y-54.16%
OCF growth 3Y-22.88%
OCF growth 5Y-13.5%

BAXTER INTERNATIONAL INC / BAX FAQ

What is the fundamental rating for BAX stock?

ChartMill assigns a fundamental rating of 3 / 10 to BAX.


Can you provide the valuation status for BAXTER INTERNATIONAL INC?

ChartMill assigns a valuation rating of 6 / 10 to BAXTER INTERNATIONAL INC (BAX). This can be considered as Fairly Valued.


What is the profitability of BAX stock?

BAXTER INTERNATIONAL INC (BAX) has a profitability rating of 3 / 10.


Can you provide the expected EPS growth for BAX stock?

The Earnings per Share (EPS) of BAXTER INTERNATIONAL INC (BAX) is expected to decline by -0.01% in the next year.


How sustainable is the dividend of BAXTER INTERNATIONAL INC (BAX) stock?

The dividend rating of BAXTER INTERNATIONAL INC (BAX) is 4 / 10 and the dividend payout ratio is -119.65%.